NEW YORK (GenomeWeb News) — Thermo Fisher Scientific said today it has expanded its Biomarker Research Initiative in Mass Spectrometry program to include new technology and programs that involve clinical validation and clinical application assays.
The BRIMS program, begun in 2004 with Massachusetts General Hospital, initially focused on discovering protein biomarkers, particularly those related to cardiovascular disease. It was intended to use Thermo’s LTQ FT and LTQ Orbitrap and other tools with Mass General’s bank of plasma samples.
BRIMS will now use Thermo’s TSQ Quantum triple-quadrupole platform and its TurboFlow sample-prep technology to develop assays for peptides and protein-biomarker quantitation.